

TSRX | Trius Therapeutics | Profile | Summary

Trius Therapeutics, TSRX, has just raised \$50 Million Dollars. The interesting thing about the company's IPO was, the size and the price of the offering was cut down almost in half before the IPO, thus providing an excellent opportunity and a little cushion for those who buy the stock in the open market.

We believe this could be a good opportunity for investors with long term horizon and risk tolerance. Remember after all it is developing a drug that has not been approved by the FDA yet. We also like to point out that it is suitable only for investors with high degree of risk tolerance and who are not looking for a quick pop.

TSRX is developing life-threatening bacterial infections like the antibiotic-resistant strains of staph infections, known as MRSA. The company says its drug is more potent and can be easily administered than what is currently being offered . In addition it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by bacteria of the gram-negative and gram-positive categories.

Source: The Company, OxBridgeResearch, PennyStockMonster, OTCking
Category: MRSA, Staph infection, IPO, Bio Pharma, Bio Tech.
A20100805